Clinical Description of a Bronchoscopic Approach to Ablate Lung Nodules Using the Emprint™ Ablation Catheter

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-02-27

Study Completion Date

2020-10-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this investigation is to characterize the safety and performance of the Emprint™ Ablation Catheter Kit with Thermosphere™ Technology in clinical use.

This is a prospective, single-arm, multicenter, non-randomized study. Up to 3 sites in up to 3 countries will enroll up to 30 subjects in total. The study is designed to characterize the safety and performance of the bronchoscopic ablation procedure using the Emprint™ Ablation Catheter Kit with Thermosphere™ Technology.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)

NCT02323854

Lung Cancer

COMPLETED NA

Safety and Efficacy of Cryoablation for Metastatic Lung Tumors

NCT01307501

Metastatic Lung Cancer

COMPLETED NA

ENB Guided RFA for Early-stage Peripheral Lung Cancer

NCT03009630

Lung Cancer

UNKNOWN NA

Transbronchial Ablation for Peripheral Lung Tumor

NCT02972177

Lung Cancer

UNKNOWN NA

ENB-guided Ablation Therapy Combined With VATS in the Treatment of MPLC

NCT04730453

Lung Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this prospective, single-arm, multicenter, non-randomized study is to characterize the safety of the Emprint™ Ablation Catheter Kit with Thermosphere™ Technology device in subjects undergoing lung ablation procedures.

The primary endpoint is the composite rate of adverse events related to the Emprint™ Ablation Catheter Kit with Thermosphere™ Technology through 1-month follow-up.

The following secondary endpoints will be evaluated:

* Composite rate of serious adverse events related to the Emprint™ Ablation Catheter Kit with Thermosphere™ Technology through 1-month follow-up.
* Composite rate of all adverse events related to the procedure or study devices through 1-month follow-up.
* Composite rate of all serious adverse events related to the procedure or study devices through 1-month follow-up.
* Patient satisfaction and pain (Bronchoscopic Ablation Patient Pain and Satisfaction Survey)
* Quality of life (EQ-5D Scale)
* Technical success
* Technique efficacy

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer, Lung Cancer, Metastatic to Lung

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bronchoscopic ablation catheter

The Emprint™ Ablation Catheter Kit with Thermosphere™ Technology is deployed endoscopically and will be used to conduct bronchoscopic ablations in the lung using the superDimension™ navigation system.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is ≥ 18 years of age
2. Subject has provided informed consent
3. Subject is able and willing to comply with the study follow-up schedule
4. Subject has a definitive diagnosis of cancer in the lung
5. Target nodule is ≤ 30mm in maximum diameter
6. There is ≥ 5mm of nodule-free lung parenchyma between target nodule and pleura or fissure
7. Subject is a candidate for an elective electromagnetic navigation bronchoscopy (ENB) procedure
8. Subject is a candidate for an elective lung ablation procedure according to standard of care and product Instructions for Use
9. Subject is not a candidate for lung surgery or refuses lung surgery
10. Subject is not a candidate for stereotactic body radiation therapy (SBRT) or refuses SBRT

Exclusion Criteria

1. Target nodule is abutting main stem bronchus, main pulmonary vasculature, esophagus and/or trachea
2. Patients currently diagnosed with Global Initiative for Chronic Obstructive Lung Disease (GOLD) Stage IV emphysema
3. Female subjects who are pregnant or nursing as determined by standard site practices
4. Subject has participated in an investigational drug or device research study within 30 days of enrollment that would interfere with this study
5. The investigator determines that participation in the study may jeopardize the safety or welfare of the subject

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No